Overall verdict
Not rated
N/A
1-year performance
—
Score breakdown
HJ Science Co., Ltd. engages in research and development of new small molecule drugs in the People's Republic of China. It focuses on autoimmune, metabolic diseases, and oncology disorders. The company's core product pipeline includes HJ787, a selective TYK2 inhibitor intended for the topical treatment of atopic dermatitis (AD), acne vulgaris (AV), neurodermatitis (ND), and psoriasis (PS), as well as oral treatment of AD, AV, ND, and PS in the autoimmune sector ;
HJ178, an orally available agent for type 2 diabetes, and potentially overweight or obesity in the metabolic sector ; and HJ891, an oral KRAS inhibitor intended for the treatment of non-small-cell lung cancer. It is also developing HJ197 in clinical-stage for treatment of hepatocellular carcinoma and solid tumors; and five preclinical drug candidates comprising HJ356, HJ093, HJ199, HJ198, and HJ086 for treatment of cardiovascular disease and atherosclerosis. The company was incorporated in 2017 and is headquartered in Chengdu, China.
Sector
Health Care
Industry
Biotechnology
Primary listing
Hkex
China
CEO
Dr. Jianxin Ji
Founded
2017
Employees
115
Revenue / employee
122 429 HKD
Next earnings
November 27, 2026 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
—
52-week low
—
1-year performance
—
Year-to-date performance
—
Position in the 52-week range
—
Gross margin 100.0%, net margin 0.0%, ROIC -28.4%, ROE -40.2%.
Net margin
0.00%
Negative
Sector -213.59%|S&P 13.35%
Gross margin
100.00%
Exceptional
Return on equity (ROE)
-40.18%
Negative
Sector -55.61%|S&P 16.98%
Return on invested capital (ROIC)
-28.40%
Negative
Free cash flow margin (FCF)
-701.30%
Negative
Growth
10.0/10Revenue up 107.9% over 1 year.
Revenue (trailing 12 months)
14.1M HKD
Revenue growth (1y)
107.90%
Hyper-growth
Revenue growth (3y)
—
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
Sector 11.0x|S&P 22.1x
Forward P/E (adjusted)
—
EV / EBITDA
—
N/A (loss)
Sector 16.5x|S&P 14.9x
PEG
—
Sector 0.38|S&P 0.84
Market cap
1.8Md HKD
Financial strength
3.5/10Cash covers 5730.4% of the debt, net debt/EBITDA 8.8x.
Net debt / EBITDA
8.8x
Stretched
Gearing (net debt / equity)
-102.30%
Net cash
Cash
1.4Md HKD
Cash / market cap
80.72%
Very solid
Cash / total debt
5730.45%
Net cash
Interest coverage
-972.8x
Stretched
Net debt
-1.4Md HKD
Equity
1.4Md HKD
Closed daily candles, 5 months
Last close on November 20, 2026: 24.32 HKD
- MM2029.76
- MM5034.53
- RSI 1430.2
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
50-day average slope, 1 month
-14.04%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
5.38 % per day
Volatility change
+7.26%
Same sub-industry: 797 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALERS | 4.5 | 4.5 | 284M USD | 36.9x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.0 % | 8.2 % | ||
| 2 | BNTC | 4.0 | N/A | 286M USD | Not meaningful (loss) | — | — | -37.5 % | 3.2x | -6.2 % | -40.5 % | ||
| 3 | SPRY | 2.7 | 3.0 | 298M USD | Not meaningful (loss) | -163.6 % | 16.0 % | -112.7 % | 0.1x | -61.5 % | -59.0 % | ||
| 4 | 7630 | 2.7 | 2.7 | 292M USD | Not meaningful (loss) | -213.6 % | 14.1 % | -60.5 % | 5.4x | -4.8 % | -77.2 % | ||
| 5 | 4894 | 2.1 | 1.5 | 296M USD | Not meaningful (loss) | -1478.4 % | -52.6 % | -15.8 % | 5.0x | — | -13.8 % | ||
| 6 | EVMN | 2.1 | 0.9 | 291M USD | Not meaningful (loss) | — | -100.0 % | -68.1 % | 1.3x | -31.3 % | -63.4 % | ||
| 7 | 6945 | 1.5 | N/A | 287M USD | Not meaningful (loss) | — | — | -22.4 % | 4.5x | -4.1 % | -7.9 % | ||
| 8 | 2617 | 1.5 | N/A | 294M USD | Not meaningful (loss) | -738.1 % | — | -36.0 % | 3.6x | -12.3 % | -96.8 % | ||
| 9 | HJ ScienceAnalysed | 6132 | N/A | N/A | 228M USD | — | 0.0 % | 107.9 % | -28.4 % | 8.8x | -5.5 % | — |
